Results were unprecedented: For context, the average STEP 1 participant lost about 15% of body weight over 68 weeks
This transparent approach is critical when working with a compound that is attracting significant interest in the context of weight management research
Consequently, GLP-1RAs are recommended as a first-line injectable therapy for patients requiring pharmacological intervention to achieve glycemic control [7]
Cardiometabolic risk factors, such as C-reactive protein, lipids, and blood pressure, were also reduced with semaglutide treatment compared with placebo [49]
[1] [2] This does not mean the combination has been proven saferather, it has not been specifically studied
(A sedentary adult generally needs to take in between 1,600 and 2,400 calories to maintain their current weight)